no significant adverse health effect to the patient is expected.

Actions Taken To Prevent Recurrence

**Licensee**—The licensee modified its procedure to insert the needles that hold the prostate in place prior to obtaining the ultrasound images instead of immediately before the seed needles are inserted. In addition, the sagittal image will be captured at the time of planning image acquisition and confirmed periodically throughout the case, and the radiation oncologist will personally confirm the location of the reference base prior to dispensing the first seed.

**State**—The Louisiana Department of Environmental Quality conducted an investigation, reviewed the licensee’s corrective actions, and found the corrective actions to be adequate.

AS10–07 Medical Event at Mayo Clinic in Rochester, Minnesota

**Date and Place**—March 23, 2010, Rochester, Minnesota.

**Nature and Probable Consequences**—The Mayo Clinic (the licensee) reported a medical event associated with an HDR biliary treatment for liver carcinoma containing 329 GBq (8.9 Ci) of iridium-192. A patient was prescribed to receive four fractionated doses totaling 16 Gy (1.600 rad) to the liver. The treatment to the liver should have produced an estimated dose to the duodenum (wrong treatment site) of 1.2 Gy (120 rad) but as a result of the event it received a dose of about 10 Gy (1,000 rad). The patient and referring physician were informed of this event.

During the second fractioned treatment, the measurement cable was inserted into the catheter and it was noted that it extended about 17 cm beyond the programmed treatment distance used during the first fractioned treatment. It was concluded that the measurement wire on the first treatment had met with some resistance at a tight bend and that it was not at the end of the catheter. This resulted in overdosing the duodenum (wrong treatment site). Upon discovery of the treatment distance error and overdose, the licensee changed the written directive to add a fifth fractioned treatment to correct for the underdose of the liver. A lesser total dose to the liver was given because of concerns regarding the dose already received by the duodenum. The authorized user concluded that no chronic health effect to the patient is expected.

**Cause(s)**—The medical event was caused by human error in failing to verify that the correct catheter length was entered into the HDR unit.

Actions Taken To Prevent Recurrence

**Licensee**—The licensee committed to taking several corrective actions including the imaging of inserted catheters prior to treatments and performing catheter length checks prior to HDR treatments.

**State**—On April 6, 2010, the Minnesota Department of Health (MDH) staff performed a reactive inspection of the licensee’s HDR program. The MDH approved the licensee’s corrective actions and did not take enforcement action.

NRC10–08 Medical Event at Providence Hospital in Novi, Michigan

**Date and Place**—August 30, 2010, Novi, Michigan.

**Nature and Probable Consequences**—Providence Hospital (the licensee) reported that a medical event occurred associated with an anal brachytherapy treatment using 32 seeds containing iodine-125. The intended dose was 90 Gy (9,000 rad) to the tumor. Instead, the patient’s seminal vesicle received 19.79 Gy (1,979 rad) more than intended and the bladder received 3.68 Gy (368 rad) more than intended. The patient and referring physician were informed of this event.

On September 1, 2010, a follow-up CT scan showed that the permanent implants had been inserted about 4 cm from the intended location. The licensee reported that the tumor near the anus and rectum received a maximum dose of 8 Gy (800 rad). The licensee calculated the dose difference to the surrounding tissue as a result of the improper permanent implant placement. The licensee concluded that no significant adverse health effect to the patient is expected.

**Cause(s)**—The licensee determined that the cause of the event was that they did not use tissue markers to confirm source placement and the insertion needle did not have a visible mark to ensure proper depth placement.

Actions Taken To Prevent Recurrence

**Licensee**—Procedures were modified to administer sources as prescribed in the written directive as follows: (1) Any interstitial procedure that requires the use of fluoroscopy alone will be done with the use of tissue markers to confirm source placement, and (2) interstitial procedures that use fluoroscopy alone will have needle depth verified. The licensee completed training of licensee staff on the event and the corrective actions by October 1, 2010.

**NRC**—The NRC’s Region III staff reviewed and concurred on the licensee’s corrective actions. The NRC has retained the services of an independent medical consultant to determine if any significant health effects to the patient are expected.

Dated at Rockville, Maryland, this 23rd day of June, 2011.

For the Nuclear Regulatory Commission.

Andrew L. Bates,

**acting secretary of the commission.**

**[FR Doc. 2011–16266 Filed 6–28–11; 8:45 am]**

**BILLING CODE 7590–01–P**

---

**OVERSEAS PRIVATE INVESTMENT CORPORATION**

[OMB–3420–0011; OPIC–115]

**Submission for OMB Review**

**AGENCY:** Overseas Private Investment Corporation (OPIC).

**ACTION:** Request for approval.

**SUMMARY:** Under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35), agencies are required to publish a Notice in the Federal Register notifying the public that the agency has prepared an information collection for OMB review and approval. (Comments were solicited in the 60 day notice, posted on [October 2, 2007], and no comments were received.)

**DATES:** This 30-day notice is to inform the public, that this collection is being submitted to OMB for approval.

**ADDRESSES:** Copies of the subject form may be obtained from the Agency submitting officer.

**FOR FURTHER INFORMATION CONTACT:**

OPIC Agency Submitting Officer: Essie Bryant, Record Manager, Overseas Private Investment Corporation, 1100 New York Avenue, NW., Washington, DC 20527; (202) 336–8563.

**Summary Form Under Review**

**Type of Request:** Revised form.

**Title:** Application for Financing.

**Form Number:** OPIC–115.

**Frequency of Use:** Once per investor per project.

**Type of Respondents:** Business or other institution (except farms); individuals.

**Standard Industrial Classification Codes:** All.

**Description of Affected Public:** U.S. companies or citizens investing overseas.

**Reporting Hours:** 9 hours per project.

**Number of Responses:** 190 per year.

**Federal Cost:** $12,754.

**Authority for Information Collection:** Sections 231, 234(a), 239(d), and 240A of the Foreign Assistance Act of 1961, as amended.
### OVERSEAS PRIVATE INVESTMENT CORPORATION

#### Submission for OMB Review

**AGENCY:** Overseas Private Investment Corporation (OPIC).

**ACTION:** Request for approval.

**SUMMARY:** Under the provisions of the Paperwork Reduction Act (44 U.S.C. chapter 35), agencies are required to publish a Notice in the Federal Register notifying the public that the agency has prepared an information collection for OMB review and approval.

**DATES:** This 30-day notice is to inform the public that this collection is being submitted to OMB for approval.

**ADDRESSES:** Copies of the subject form may be obtained from the Agency submitting officer.

**FOR FURTHER INFORMATION CONTACT:** OPIC Agency Submitting Officer: Essie Bryant, Record Manager, Overseas Private Investment Corporation, 1100 New York Avenue, NW., Washington, DC 20527; (202) 336–8563.

**Summary Form Under Review**

- **Type of Request:** New form.
- **Title:** Short—Form Application for Political Risk Insurance.
- **Form Number:** OPIC–247.
- **Frequency of Use:** Once per investor per project.
- **Type of Respondents:** Business or other institution (except farms); individuals.
- **Standard Industrial Classification Codes:** All.
- **Description of Affected Public:** U.S. companies or citizens investing overseas.
- **Reporting Hours:** 2 hours per project.
- **Number of Responses:** 50 per year.
- **Federal Cost:** $5,000.

**Authority for Information Collection:** Sections 231, 234(a), 239(d), and 240A of the Foreign Assistance Act of 1961, as amended.

### OVERSEAS PRIVATE INVESTMENT CORPORATION

#### Submission for OMB Review

**AGENCY:** Overseas Private Investment Corporation (OPIC).

**ACTION:** Request for approval.

**SUMMARY:** Under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35), agencies are required to publish a Notice in the Federal Register notifying the public that the agency has prepared an information collection for OMB review and approval.

**DATES:** This 30-day notice is to inform the public that this collection is being submitted to OMB for approval.

**ADDRESSES:** Copies of the subject form may be obtained from the Agency submitting officer.

**FOR FURTHER INFORMATION CONTACT:** OPIC Agency Submitting Officer: Essie Bryant, Record Manager, Overseas Private Investment Corporation, 1100 New York Avenue, NW., Washington, DC 20527; (202) 336–8563.

**Summary Form Under Review**

- **Type of Request:** Extension, without change, of a currently approved collection.
- **Title:** Self-Monitoring Questionnaire for Insurance and Finance Projects.
- **Form Number:** OPIC 162.
- **Frequency of Use:** One per investor per project.
- **Type of Respondents:** Business or other institution (except farms); individuals.
- **Standard Industrial Classification Codes:** All.
- **Description of Affected Public:** U.S. companies or citizens investing overseas.
- **Reporting Hours:** 4 hours per form.
- **Number of Responses:** one per year.
- **Federal Cost:** $0.

**Authority for Information Collection:** Sections 231, 234(a), 239(d), and 240A of the Foreign Assistance Act of 1961, as amended.

### OVERSEAS PRIVATE INVESTMENT CORPORATION

#### Submission of OMB review; comments request

**AGENCY:** Overseas Private Investment Corporation (OPIC).

**ACTION:** Request for comments.

**SUMMARY:** Under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35), agencies are required to publish a Notice in the Federal Register notifying the public that the Agency has prepared an information collection request for OMB review and approval and has requested public review and comment on the submission. Comments are being solicited on the need for the information; the accuracy of the Agency’s burden estimate; the quality, practical utility and clarity of the information to be collected; and on ways to minimize the reporting burden, including automated collection techniques and uses of other forms of technology. The proposed form under review, OPIC form 241, is summarized below.

**DATES:** Comments must be received within 30 calendar-days of publication of this Notice.

**ADDRESSES:** Copies of the subject form and the request for review prepared for submission to OMB may be obtained from the Agency Submitting Officer. Comments on the form should be submitted to the Agency Submitting Officer.

**FOR FURTHER INFORMATION CONTACT:** Agency Submitting Officer: Essie Bryant, Records Management Officer, Overseas Private Investment Corporation, 1100 New York Avenue, NW., Washington, DC 20527; (202) 336–8563.

**Summary of Form Under Review:**

- **Type of Request:** New Form.